These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38125558)

  • 21. Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
    Stafford S; Bech PG; Fridhammar A; Miresashvili N; Nilsson A; Willis M; Liu A
    Appl Health Econ Health Policy; 2022 Jul; 20(4):543-555. PubMed ID: 35344191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
    Kimura T; Kubo M; Takahashi K; Wamata R; Iwamoto Y; Iwamoto H; Katakura Y; Sanada J; Fushimi Y; Shimoda M; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2024; 2024():5880589. PubMed ID: 38223524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
    Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
    Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
    Zhang X; McAdam Marx C
    J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
    Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
    Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
    Webb N; Orme M; Witkowski M; Nakanishi R; Langer J
    Diabetes Ther; 2018 Jun; 9(3):973-986. PubMed ID: 29574633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 32. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
    Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
    Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
    Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
    J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
    Ruan Z; Yang L; Shi H; Yue X; Wang Y; Liang M; Hu H
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):221-233. PubMed ID: 33317348
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
    Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
    Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
    Ji L; Dong X; Li Y; Li Y; Lim S; Liu M; Ning Z; Rasmussen S; Skjøth TV; Yuan G; Eliaschewitz FG
    Diabetes Obes Metab; 2021 Feb; 23(2):404-414. PubMed ID: 33074557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
    Tham LS; Pantalone KM; Dungan K; Munir K; Tang CC; Konig M; Kwan AYM
    Diabetes Obes Metab; 2022 Feb; 24(2):302-311. PubMed ID: 34697882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.